ALTERITY THERAPEUTICS

alterity-therapeutics-logo

Alterity Therapeutics has developed a proprietary library of class-leading chemical compounds. This library is combined with a drug development program to explore novel therapeutics in multiple disease indications. The scientific focus of the company is upon neurological diseases, particularly Alzheimer‘s, Parkinson‘s and Huntington‘s diseases.

#SimilarOrganizations #People #Event #Website #More

ALTERITY THERAPEUTICS

Social Links:

Industry:
Biotechnology Chemical Medical

Founded:
1997-01-01

Address:
Parkville, New South Wales, Australia

Country:
Australia

Website Url:
http://www.alteritytherapeutics.com

Total Employee:
11+

Status:
Active

Contact:
+61 3 9824 8166

Email Addresses:
info@pranabio.com

Total Funding:
31.4 M USD

Technology used in webpage:
Euro GoDaddy


Similar Organizations

accent-therapeutics-logo

Accent Therapeutics

Accent Therapeutics is a biopharmaceutical company.

affimed-logo

Affimed

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

scholar-rock-logo

Scholar Rock

Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.

Current Employees Featured

not_available_image

Dianne Angus
Dianne Angus COO @ Alterity Therapeutics
COO

not_available_image

Phillip Hains
Phillip Hains CFO @ Alterity Therapeutics
CFO
2023-01-01

not_available_image

Geoffrey Paul Kempler
Geoffrey Paul Kempler CEO & Founder @ Alterity Therapeutics
CEO & Founder

not_available_image

David Stamler
David Stamler Chief Executive Officer @ Alterity Therapeutics
Chief Executive Officer
2021-01-01

Founder


not_available_image

Geoffrey Paul Kempler

Stock Details


Company's stock symbol is ASX:ATH

Key Employee Changes

Date New article
2023-12-21 Alterity Therapeutics appoints Phillip Hains as CFO

Official Site Inspections

http://www.alteritytherapeutics.com Semrush global rank: 8.83 M Semrush visits lastest month: 459

  • Host name: syn05de.syd7.hostyourservices.net
  • IP address: 110.232.143.144
  • Location: Brisbane Australia
  • Latitude: -27.4732
  • Longitude: 153.0215
  • Timezone: Australia/Brisbane
  • Postal: 4000

Loading ...

More informations about "Alterity Therapeutics"

Home - Alterity Therapeutics

Apr 29, 2025 We exist to create an alternate future for people with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people living with these debilitating diseases.See details»

About Multiple System Atrophy - Alterity Therapeutics

See details»

Alterity Therapeutics - LinkedIn

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases.See details»

Alterity Therapeutics Announces Multiple Oral and Poster

15 hours ago The Congress is presented by Mission MSA, a non-profit organization dedicated to improving the quality of life and building hope for people affected by MSA through support …See details»

Alterity Therapeutics - Crunchbase Company Profile & Funding

ATH434: An oral agent that inhibits the aggregation of proteins such as α‑synuclein in the central nervous system, currently in Phase 2 clinical trials for Multiple System Atrophy (MSA).See details»

Alterity Therapeutics (ATHE) Company Profile & Description

Apr 29, 2025 Ticker Symbol: ATHE: Exchange: NASDAQ: Fiscal Year: July - June: Reporting Currency: AUD: CIK Code: 0001131343: CUSIP Number: 02155X106: ISIN Number: …See details»

ALTERITY THERAPEUTICS LIMITED - Dun & Bradstreet

Company Description: Prana Biotechnology wants to give Alzheimer's disease a prize fight. The biotechnology company is developing therapies for age-related degenerative conditions, …See details»

Alterity Therapeutics Granted U.S. FDA Fast Track - GlobeNewswire

2 days ago mmacdonald@alteritytherapeutics.com +61 3 9349 4906. Ana Luiza Harrop we-aualteritytherapeutics@we-worldwide.com +61 452 510 255. U.S. Remy Bernarda …See details»

Alterity Therapeutics

Alterity is dedicated to creating an alternate future for people living with neurodegenerative diseases. Alterity means the state of being different Our goal is to modify the course of diseaseSee details»

Alterity Therapeutics Receives U.S. FDA Approval for …

Sep 20, 2022 For further information please visit the Company's web site at www.alteritytherapeutics.com. Authorisation & Additional information This announcement was …See details»

Alterity Therapeutics - Craft

Oct 28, 2024 Alterity Therapeutics is a company researching and developing therapies to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurodegenerative …See details»

Alterity - 2025 Company Profile & Funding - Tracxn

Apr 27, 2025 Alterity has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Feb 09, 2021 for $495K. 1 investor participated in its latest round, which …See details»

Alterity Therapeutics - Overview, News & Similar companies

Apr 30, 2024 Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE …See details»

Alterity Therapeutics Information - RocketReach

Alteritytherapeutics.com; View Similar People. Related Companies Respiri Limited. 18 $750k Bio-Strategy. 103 $25.5m PolyActiva. 24 $4m Acrux. 98 $90b AusBiotech. 61 $24.7m In Vitro …See details»

The Science - Alterity Therapeutics

REDISTRIBUTE: We know there is excess, loosely bound iron in the brains of patients with MSA. And it is known that this increased iron contributes to the pathology of the disease. ATH434 is …See details»

Alterity Therapeutics Company Overview, Contact Details

Jan 4, 2019 Alterity Therapeutics Ltd. launches Appendix 4C Quarterly Cash Flow Report. MELBOURNE, Australia and SAN FRANCISCO, July 31, 2024 (GLOBE NEWSWIRE) - …See details»

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ...

2 days ago – Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 …See details»

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ...

– Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 5 May …See details»

Alterity Therapeutics Announces Presentation of New Data

Nov 16, 2023 For further information please visit the Company’s web site at www.alteritytherapeutics.com. Authorisation & Additional information This announcement was …See details»

Alterity Therapeutics - Facebook

Alterity Therapeutics. 169 likes · 10 talking about this. Creating an alternate future for people living with neurodegenerative diseaseSee details»

linkstock.net © 2022. All rights reserved